Fairmount Funds Management LLC Reduces Stake in Enliven Therapeutics to 3.1%

This Amendment No. 5 to Schedule 13G, filed on May 15, 2026, details the beneficial ownership of Enliven Therapeutics, Inc. (ELVN) by Fairmount Funds Management LLC and associated reporting persons, including Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak. As of the event date on March 31, 2026, the reporting persons collectively hold 1,855,644 shares of Common Stock, representing 3.1% of the company based on 59,800,406 shares outstanding. This filing marks a decrease in ownership to below the 5% threshold, as the reporting persons now indicate they have ceased to be beneficial owners of more than five percent of the class of securities. Fairmount serves as the investment adviser for Fund II and maintains shared voting and dispositive power over the reported shares. The filing confirms that the securities were not acquired for the purpose of changing or influencing the control of the issuer. This amendment updates previous filings made between April 2023 and August 2025.